Vertex Pharmaceuticals’ (VRTX) latest cystic fibrosis drug — the Boston biotech’s third product to reach the market — is off to a strong commercial start.
Sales of the new Vertex drug, marketed under the brand name Symdeko, totaled $34 million in the first quarter, the company said Thursday. The FDA approved Symdeko in the middle of February.
With the Symdeko contribution, Vertex reported total cystic fibrosis drug sales of $638 million in the quarter, a 33 percent increase from the same period one year ago and ahead of Wall Street consensus expectations.
About the Author Reprints
